An economic evaluation of intensive hypertension control in CKD patients: a cost-effectiveness study

Background Studies have suggested that intensive hypertension control in patients with a high risk of cardiovascular disease (CVD) is both effective and economically feasible.

The purpose of this study is to conduct an economic evaluation of intensive hypertension control targeting chronic kidney disease (CKD) patients using the representative data in Korea.

Methods We used a Markov decision model to compare both cost and effectiveness of intensive hypertension control versus standard hypertension control in hypertensive CKD patients.

Model parameters were estimated with the data from the National Health Insurance Service (NHIS)-National Sample Cohort, as well as latest literature.

One-way sensitivity analysis was conducted to test the effect of variation in key parameters on the model outcome.

Results For CKD patients with hypertension, intensive hypertension control would cost more but increase utilities, compared to standard hypertension control.

The incremental cost-effectiveness ratio (ICER) for intensive hypertension control in CKD patients was projected at 18,126 USDs per quality-adjusted life year (QALY) compared to standard hypertension control.

The results of sensitivity analysis suggest that the results are overall robust.

Conclusions This study finds that intensive hypertension control in CKD patients in Korea is economically sound.

This information is expected to be useful for clinicians in managing hypertension of CKD patients and policymakers when making decisions.